Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
4.620
+0.110 (2.44%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Cogent Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Cogent Biosciences stock have an average target of 14.17, with a low estimate of 8.00 and a high estimate of 21. The average target predicts an increase of 206.71% from the current stock price of 4.62.
Analyst Consensus: Buy
* Price targets were last updated on Mar 7, 2025.
Analyst Ratings
The average analyst rating for Cogent Biosciences stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 2 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Initiates $17 | Buy | Initiates | $17 | +267.97% | Mar 7, 2025 |
| Baird | Baird | Hold Maintains $10 → $8 | Hold | Maintains | $10 → $8 | +73.16% | Feb 27, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $17 → $14 | Strong Buy | Maintains | $17 → $14 | +203.03% | Jan 14, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades $15 | Strong Buy → Hold | Downgrades | $15 | +224.68% | Dec 11, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
44.96M
EPS This Year
-2.24
from -2.46
EPS Next Year
-1.92
from -2.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 119.5M | 640.9M | ||
| Avg | n/a | 45.0M | 211.0M | ||
| Low | n/a | n/a | 63.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,325.7% | ||
| Avg | - | - | 369.3% | ||
| Low | - | - | 41.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.72 | -1.48 | 1.18 | ||
| Avg | -2.24 | -1.92 | -0.83 | ||
| Low | -2.71 | -3.00 | -1.43 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.